...
首页> 外文期刊>Cellular Physiology and Biochemistry >Sonidegib, a Novel Inhibitor of Suicidal Erythrocyte Death
【24h】

Sonidegib, a Novel Inhibitor of Suicidal Erythrocyte Death

机译:Sonidegib,一种自杀性红细胞死亡的新型抑制剂

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background/Aims The Hedgehog pathway disrupting drug sonidegib is used in the treatment of basal cell carcinoma. Side effects of sonidegib include anemia, which could result either from impaired erythropoiesis or from loss of erythrocytes e.g. due to suicidal erythrocyte death or eryptosis, which is characterized by cell membrane scrambling with phosphatidylserine translocation to the cell surface and by cell shrinkage. Eryptosis is stimulated by cell stress, including energy depletion, hyperosmotic shock, oxidative stress and excessive increase of cytosolic Ca2+ activity ([Ca2+]i). The present study explored, whether sonidegib exerts an effect on eryptosis. Methods Human erythrocytes have been treated with energy depletion (glucose withdrawal for 48 hours), hyperosmotic shock (addition of 550 mM sucrose for 6 hours), oxidative stress (addition of 0.3 mM tert-butylhydroperoxide [tBOOH] for 50 min) or Ca2+ ionophore ionomycin (1 µM for 60 min) in absence and presence of sonidegib (2-6 µg/ ml). After treatment flow cytometry was employed to quantify phosphatidylserine exposure at the cell surface from annexin-V-binding, and cell volume from forward scatter. Hemolysis was estimated from the hemoglobin concentration in the supernatant. Results In the absence of cell stress exposure to sonidegib did not significantly modify annexin-V-binding or forward scatter, but triggered hemolysis. Energy depletion, hyperosmotic shock, oxidative stress and ionomycin, all markedly and significantly increased the percentage of annexin-V-binding erythrocytes, and decreased the forward scatter. Sonidegib significantly blunted the effect of energy depletion, hyperosmotic shock, and oxidative stress, but not of ionomycin on annexin-V-binding. Sonidegib further significantly blunted the effect of energy depletion, but not of hyperosmotic shock, oxidative stress, and ionomycin on forward scatter. Conclusions Sonidegib is a novel inhibitor of erythrocyte cell membrane scrambling following energy depletion, hyperosmotic shock and oxidative stress.
机译:背景/目的Hedgehog途径破坏药物Sonidegib用于治疗基底细胞癌。 Sonidegib的副作用包括贫血,这可能是由于红细胞生成功能受损或红细胞丢失(例如由于自杀性红细胞死亡或隐匿,其特征在于细胞膜被磷脂酰丝氨酸易位到细胞表面而争夺,并且细胞收缩。细胞应力(包括能量消耗,高渗性休克,氧化应激和胞浆Ca2 +活性([Ca2 +] i)的过度增加)刺激了加密作用。本研究探讨了sonidegib是否对加密产生作用。方法对人体红细胞进行能量消耗(停药48小时),高渗休克(添加550 mM蔗糖6小时),氧化应激(添加0.3 mM叔丁基氢过氧化物[tBOOH] 50分钟)或Ca2 +离子载体治疗在不存在sonidegib(2-6 µg / ml)的情况下加入ionomycin(1 µM,持续60分钟)。处理后,采用流式细胞术从膜联蛋白-V-结合定量分析细胞表面磷脂酰丝氨酸的暴露,并从前向散射定量分析细胞的体积。从上清液中的血红蛋白浓度估计溶血。结果在缺乏细胞应激的情况下,sonidegib暴露不会显着改变膜联蛋白V结合或前向散射,但会触发溶血。能量耗竭,高渗性休克,氧化应激和离子霉素均显着显着增加了膜联蛋白-V结合红细胞的百分比,并降低了前向散射。 Sonidegib显着减弱了能量消耗,高渗休克和氧化应激的作用,但离子霉素对膜联蛋白-V结合的作用却没有。 Sonidegib进一步显着减弱了能量消耗的作用,但对高渗性休克,氧化应激和离子霉素对前向散射的作用却没有。结论Sonidegib是一种新的抑制能量消耗,高渗性休克和氧化应激引起的红细胞膜混乱的抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号